MVP 3.61% 40.0¢ medical developments international limited

Another Positive Study, page-156

  1. 4,010 Posts.
    lightbulb Created with Sketch. 1394
    MethOxyfluraNe in InTerventiOnal Radiology (MONITOR): A randomised controlled trial
    Ross Copping et al. J Med Imaging Radiat Oncol.2024.
    https://pubmed.ncbi.nlm.nih.gov/38923825/

    Results: One hundred and sixty-nine patients received methoxyflurane and 145 received placebo. Baseline characteristics were similar between the two groups. The methoxyflurane group had lower pain and anxiety scores throughout the procedure (P < 0.001) with 2.5 times less pain (VAS 1.08/10) and 1.6 times less anxiety (VAS 0.97/10) on average. Lower post-procedure pain (mean 0.72 vs 1.44; P < 0.001) and anxiety (mean 0.55 vs 1.13; P = 0.008) were also observed with methoxyflurane. There were no drug or major procedure-related adverse events.

    Conclusion: The results of this study suggest that methoxyflurane provides safe and effective analgesia and anxiolysis for some procedures in IR.
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
(20min delay)
Last
40.0¢
Change
-0.015(3.61%)
Mkt cap ! $40.73M
Open High Low Value Volume
40.0¢ 41.0¢ 38.5¢ $136.7K 345.4K

Buyers (Bids)

No. Vol. Price($)
1 1000 40.0¢
 

Sellers (Offers)

Price($) Vol. No.
42.0¢ 18000 2
View Market Depth
Last trade - 15.54pm 06/08/2024 (20 minute delay) ?
MVP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.